Q-omics provides the consensus-scored UBXN10 profile across patient tissues and cancer cell-line models. UBXN10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, UBXN10 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, UBXN10 RNA expression shows 17,819 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, LUSC, and KIRP as cancer lineages where UBXN10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBXN10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBXN10 survival associations across molecular data types. UBXN10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBXN10 RNA expression–survival associations across cancer types. High UBXN10 expression shows favorable associations in BRCA, READ, KIRC, UCEC, SARC and COAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for UBXN10 RNA expression.
This table summarizes UBXN10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for UBXN10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBXN10 shows lower tumor expression in LUSC, KICH, LIHC and PRAD and higher tumor expression in KIRC and PAAD. The LUSC box plot shows higher UBXN10 RNA expression in normal versus tumor tissue (log2 FC = −2.611, t-test p < 0.001).
This table shows molecular features associated with UBXN10 in patient tissues and cancer cell lines. In patient samples, UBXN10 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, UBXN10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
